Young companies taking on checkpoint inhibitor resistance at AACR22

Overcoming checkpoint inhibitor resistance remains a hot topic at AACR in 2022, and it isn’t only the big pharmas and well-known players taking on the challenge. The presentations also feature a spate of young companies applying new targets, mechanisms and modalities to the problem.

BioCentury’s analysis of the over 5,000 abstracts released ahead of the American Association for Cancer Research (AACR) annual meeting that runs April 8-13 in New Orleans identifies more than 500 abstracts proposing strategies to address the checkpoint inhibitor resistance problem, many of which come from young, privately held companies that have previously shared little data from their programs. ...